CUREVAC N V's ticker is CVAC and the CUSIP is N2451R105. A total of 84 filers reported holding CUREVAC N V in Q3 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $783,000 | – | 99,348 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 370,385 | $17,241,000 | 4.81% |
| Novo Holdings A/S | 201,642 | $9,386,000 | 0.47% |
| Vivo Capital, LLC | 169,825 | $7,905,000 | 0.46% |
| Baillie Gifford | 3,896,475 | $181,381,000 | 0.12% |
| DekaBank Deutsche Girozentrale | 435,500 | $21,707,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 69,176 | $3,220,000 | 0.08% |
| HHLR ADVISORS, LTD. | 186,183 | $8,667,000 | 0.07% |
| Pinz Capital Management, LP | 3,600 | $168,000 | 0.06% |
| Cutler Group LLC / CA | 18,400 | $856,000 | 0.05% |
| ETF MANAGERS GROUP, LLC | 35,722 | $1,632,000 | 0.05% |